Worldwide survey of IVF practices: trigger, retrieval and embryo transfer techniques

Tobler, K.J.; Zhao, Yulian; Weissman, Ariel; Majumdar, Abha; Leong, Milton; Shoham, Zeev

doi:10.1007/s00404-014-3232-6

Cited by 25 publications

(13 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In analysis of subgroup with irregular anovulatory cycle PCOS, authors reported a development of more severe OHSS when compared to less risk, women with regular ovulatory cycles [8] , so there is a need for adequate powered RCT to explore the antagonist protocol OHSS sparing effect in women at high risk for OHSS development; namely, with high basal Antimullerian hormone (AMH), Antral follicular count (AFC) and high SE2 at ovulation triggering. GnRh agonist ovulation triggering instead of HCG as OHSS protective strategy, despite it is only possible in non-agonist based protocols as antagonist protocols as well as recently introduced progesterone primed ovarian stimulation protocol (PPOS), [30,31,32,33] was less effective than HCG triggering as regards of ongoing pregnancy rate and live birth rate [26] as well as infertility clinician still preferred HCG over GnRh agonist in antagonist protocol [28] and that recent review of utilization of GnRh agonist as ovulation triggering instead of HCG stated that this issue still needs more research [29] .…”

Section: Discussionmentioning

confidence: 99%

Calcium infusion plus or minus cabergoline for prevention of ovarian hyperstimulation syndrome: Randomized double-blind placebo-controlled trial

Sharafeldeen

2018

Evidence Based Women's Health Journal

View full text Add to dashboard Cite

Aim: To evaluate the interaction of adding oral cabergoline (OC) to calcium infusion as a preventive modality for ovarian hyperstimulation syndrome (OHSS) in risky women undergoing controlled ovarian hyperstimulation (COH) in context of in-vitro fertilization (IVF) / intracytoplasmic sperm injection (ICSI). Patients and Methods: This prospective, double-blind, randomized, placebo-controlled trial was conducted at Benha IVF center of Obstetrics and Gynecology Department of Benha University and Nour Al Hayah Fertility Center Between January 2015 and February 2016. 220 risky women for OHSS undergoing ICSI were included, they were randomized to 110 women received once daily OC for eight days, starting at HCG triggering and infusion of calcium gluconate 10 ml 10% in 200 ml 0.9% saline daily for 4 days beginning at ovum pick up (OPU), coined as calcium infusion plus group (CI+) and 110 women received only calcium infusion in the same fashion as in CI+ coined as calcium infusion minus group (CI-). The primary outcome was the overall incidence of OHSS while the secondary issues were OHSS types and grades as well as other ICSI outcomes. Results: The incidence of overall OHSS was significantly lower in calcium infusion plus oral cabergoline (CI+) group compared to calcium infusion alone (CI-) group [8/110(7.2%) in CI+ versus 18/110 (16.3%) in CI-with difference in proportion percentage point (∆PP)=-9.1%, 95% CI: -0.49, -17.4; P = 0.036]. Despite the incidence of moderate and severe OHSS was lower in CI+ than in CI-, this difference didn't reach the significance level (2.7% vs 5.4%; p = 0.3) and (0.9% versus 2.7%; ), respectively. The other COH and ICSI outcomes didn't show any statistically significant differences. Conclusion: Adding oral cabergoline to calcium infusion is effective than calcium infusion alone in the reduction of overall OHSS incidence as well as its severity at comparable pregnancy outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Calcium infusion plus or minus cabergoline for prevention of ovarian hyperstimulation syndrome: Randomized double-blind placebo-controlled trial

Sharafeldeen

2018

Evidence Based Women's Health Journal

View full text Add to dashboard Cite

show abstract

“…HCG is the most widely used trigger in current practice, being applied in more than three quarters of cycles ( 6 ). As it shares the same alpha subunit, and has 85% homology of the beta subunit as native LH, hCG activates the LH receptor ( 7 ).…”

Section: Introductionmentioning

confidence: 99%

Endocrine Requirements for Oocyte Maturation Following hCG, GnRH Agonist, and Kisspeptin During IVF Treatment

Abbara

Hunjan

et al. 2020

Front. Endocrinol.

View full text Add to dashboard Cite

Objective The maturation of oocytes to acquire competence for fertilization is critical to the success of in vitro fertilization (IVF) treatment. It requires LH-like exposure, provided by either human chorionic gonadotropin (hCG), or gonadotropin releasing hormone agonist (GnRHa). More recently, the hypothalamic stimulator, kisspeptin, was used to mature oocytes. Herein, we examine the relationship between the endocrine changes following these agents and oocyte maturation. Design Retrospective cohort study. Methods Prospectively collected hormonal data from 499 research IVF cycles triggered with either hCG, GnRHa, or kisspeptin were evaluated. Results HCG-levels (121 iU/L) peaked at 24 h following hCG, whereas LH-levels peaked at ~4 h following GnRHa (140 iU/L), or kisspeptin (41 iU/L). HCG-levels were negatively associated with body-weight, whereas LH rises following GnRHa and kisspeptin were positively predicted by pre-trigger LH values. The odds of achieving the median mature oocyte yield for each trigger were increased by hCG/LH level. Progesterone rise during oocyte maturation occurred precipitously following each trigger and strongly predicted the number of mature oocytes retrieved. Progesterone rise was positively associated with the hCG-level following hCG trigger, but negatively with LH rise following all three triggers. The rise in progesterone per mature oocyte at 12 h was greater following GnRHa than following hCG or kisspeptin triggers. Conclusion The endocrine response during oocyte maturation significantly differed by each trigger. Counter-intuitively, progesterone rise during oocyte maturation was negatively associated with LH rise, even when accounting for the number of mature oocytes retrieved. These data expand our understanding of the endocrine changes during oocyte maturation and inform the design of future precision-triggering protocols.

show abstract

“…Replacing HCG with gonadotrophin releasing hormone (GnRH) agonist for triggering final oocyte maturation has been proposed for women at high-risk for OHSS, who are pretreated with GnRH antagonist protocols, in combination with freezing all oocytes or embryos (OHSSfree clinic) (Devroey et al, 2011;Youssef et al, 2014). This strategy has gained increasing popularity in recent years (De Ziegler and Shoham, 2013;Tobler et al, 2014), as it can virtually eliminate OHSS development (Humaidan et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Association between body mass index and oocyte maturation in patients triggered with GnRH agonist who are at high risk for severe ovarian hyperstimulation syndrome: an observational cohort study

Lainas

Sfontouris

et al. 2020

Reproductive BioMedicine Online

View full text Add to dashboard Cite

Worldwide survey of IVF practices: trigger, retrieval and embryo transfer techniques

Cited by 25 publications

References 29 publications

Calcium infusion plus or minus cabergoline for prevention of ovarian hyperstimulation syndrome: Randomized double-blind placebo-controlled trial

Calcium infusion plus or minus cabergoline for prevention of ovarian hyperstimulation syndrome: Randomized double-blind placebo-controlled trial

Endocrine Requirements for Oocyte Maturation Following hCG, GnRH Agonist, and Kisspeptin During IVF Treatment

Association between body mass index and oocyte maturation in patients triggered with GnRH agonist who are at high risk for severe ovarian hyperstimulation syndrome: an observational cohort study

Contact Info

Product

Resources

About